Skip to main content
Fig. 5 | BMC Medicine

Fig. 5

From: A novel CREB5/TOP1MT axis confers cisplatin resistance through inhibiting mitochondrial apoptosis in head and neck squamous cell carcinoma

Fig. 5

CREB5 inhibits apoptosis and promotes resistance to cisplatin by TOP1MT in HNSCC cells. A Flow cytometry analysis of cisplatin-induced (5 μM) apoptosis percentage in HN4 CREB5 cells with TOP1MT knockdown. B Percent cell survival was detected by MTT when TOP1MT was knocked down in HN4 CREB5 cells. IC50cisplatin values are shown on the right. C Flow cytometry analysis of cisplatin-induced (5 μM) apoptosis percentage in HN30 CREB5 cells with TOP1MT knockdown. D Percent cell survival was detected by MTT when TOP1MT was knocked down in HN30 CREB5 cells. IC50cisplatin values are shown on the right. E Flow cytometry analysis of cisplatin-induced (20 μM) apoptosis percentage in HN4/DDP siCREB5 cells with TOP1MT overexpression. F Percent cell survival was detected by MTT when TOP1MT was knocked down in HN4/DDP siCREB5 cells. IC50cisplatin values are shown on the right. G Flow cytometry analysis of cisplatin-induced (20 μM) apoptosis percentage in HN30/DDP siCREB5 cells with TOP1MT overexpression. H Percent cell survival was detected by MTT when TOP1MT was overexpressed in HN30/DDP siCREB5 cells. IC50cisplatin values are shown on the right. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001

Back to article page